Prostate cancer decisions — 2025

The Board granted service connection for prostate cancer, resolving all doubt in the Veteran's favor and finding that his prostate cancer is related to his in-service toxic exposures.

The Board granted service connection for metastatic prostate cancer, finding that the evidence is at least in approximate equipoise regarding whether it was caused by the Veteran's conceded in-service toxic exposure risk activities.

The Board remands the claim for service connection for prostate cancer for readjudication due to new and relevant evidence being submitted.

The Board remands the Veteran's claim for service connection for prostate cancer to VA for a medical examination and opinion, as required by the PACT Act due to presumed exposure to contaminated water at Camp Lejeune.

The Board denied service connection for prostate cancer and denied increased ratings for the right knee strain, lumbar spine degenerative disc disease with sacroiliitis and IVDS. However, a 20 percent rating was granted for right knee instability.

The Board denied the veteran's claim for service connection for prostate cancer, finding no medical evidence linking his condition to his service or exposure at Camp Lejeune.

The Board remands the claims for service connection for prostate cancer and erectile dysfunction, as secondary to prostate cancer, due to a pre-decisional error of the duty to assist under the Honoring our PACT Act of 2022.

The Board remands the claims for service connection for prostate cancer and skin cancer (basal cell carcinoma) to provide the Veteran with VA examinations and opinions regarding the etiology of these conditions, including considering toxic exposure risk activities.

The Board granted service connection for prostate cancer due to conceded in-service exposure to herbicides, effective from the date of claim.

The proposed severance of service connection for prostate cancer was dismissed as the August 2024 rating decision was not a final decision.

The Board denied the veteran's claims for earlier effective dates, higher ratings, and remanded several service connection claims.

The Board remands the claim for service connection for prostate cancer due to an inadequate VA medical opinion and a need for additional evidence regarding the Veteran's treatment records.

The Board denied the Veteran's claim for service connection for prostate cancer, finding that the evidence does not support a link between the condition and his military service.

The Board denied service connection for diabetes mellitus, prostate cancer, rectal cancer, weak bladder as secondary to prostate cancer, and blood in urine/stool as secondary to rectal cancer due to lack of evidence supporting a causal relationship between the conditions and exposure to contaminated water at Camp Lejeune.

The Board granted a 60 percent rating for residuals of prostate cancer from August 10, 2022 to June 5, 2023 and denied a higher rating from June 5, 2023. The Board also remanded the issue of entitlement to a total disability rating based on individual unemployability due to service-connected disability (TDIU).

The Board remands the claims for service connection for hypertension and prostate cancer to verify the Veteran's claimed exposure to herbicide agents in the DMZ.

The Board granted service connection for autoimmune hepatitis and prostate cancer based on new evidence showing a relationship to toxic exposure during service.

The Board denied the Veteran's claims for earlier effective dates for service connection for prostate cancer, erectile dysfunction, and CAD, as these were granted under the PACT Act on August 10, 2022.

The Board denied the Veteran's claims for service connection for kidney cancer and prostate cancer, as there was no evidence of exposure to ionizing radiation during active service.

The Board granted a 60 percent disability rating for prostate cancer residuals/neurogenic bladder from July 12, 2018, to January 29, 2024, and denied a higher rating. The issues of service connection for fecal incontinence, right upper extremity tendonitis, left upper extremity tendonitis, right lower extremity tendonitis, and left lower extremity tendonitis were remanded.